Strategikon Pharma
Analysis Budgeting, Forecasting, and Outsourcing Solutions for Clinical Trials
Sophiris Bio, a urology company, has announced that PRX302, a treatment for benign prostatic hyperplasia (BPH), was well-tolerated for three months following a transrectal injection.
Sophiris Bio, a urology company, has announced that PRX302, a treatment for benign prostatic hyperplasia (BPH), was well-tolerated for three months following a transrectal injection.
The transrectal safety study was designed to assess the safety and tolerability of delivering PRX302 via a transrectal route of administration using transrectal ultrasound (TRUS).
The results support the use of a TRUS-guided injection for the delivery of PRX302 directly into the prostate; previous studies used a transperineal route.
Sophiris Bio CEO Randall Woods said that the decision to move to a transrectal route was made based on the input of advisors and leading urologists treating patients with BPH.
"The transrectal route enables PRX302 to be administered by a urologist in an office based setting, in a brief procedure that does not require catheterisation," Woods said.
"To date 126 patients with BPH have been treated with PRX302 with a similar safety and tolerability profile between the transrectal and transperineal routes of administration."
The ongoing placebo controlled, double-blind, Phase I-II study, which randomised 40 patients within one of four ascending dose cohorts, has found PRX302 continues to be well-tolerated with an adverse event profile similar to previous clinical studies using a transperineal injection.
The multicentre study also observed the improvement in the International Prostate Symptom Score (IPSS) in all cohorts.
PRX302 is designed to be a single treatment for the long-term relief of BPH symptoms, such as restricted urinary flow from enlarged prostate, without causing sexual dysfunction or sacrificing quality of life, according to the company.
Analysis Budgeting, Forecasting, and Outsourcing Solutions for Clinical Trials
Functional Service Provider
SaaS Platform Decentralizing Clinical Research at Scale